# Stem Cell Therapy for Ischemic Heart Disease | 2026 Research
> Explore stem cell applications in cardiovascular disease. Learn about isolation protocols, clinical efficacy, LVEF improvement, and heart tissue regeneration.

Tags: stem-cell-therapy, cardiovascular-disease, ischemic-heart-disease, regenerative-medicine, medical-research, cardiology
## Stem Cell Applications in Cardiovascular Disease
*   Focus: Protocols, isolation, and efficacy in Ischemic Heart Disease (IHD).

## What Are Stem Cells?
*   Key properties: Self-renewal, clonogenicity, and multipotentiality.
*   Potential to differentiate into cardiomyocytes, endothelial cells, smooth muscle cells, and fibroblasts.

## Types of Stem Cells for Heart Repair
*   **Cardiac Stem Cells (CSCs):** Tissue-specific residents (c-kit positive).
*   **Bone Marrow-Derived Cells (BMCs):** Includes CD34+ hematopoietic stem cells.
*   **Induced Pluripotent Stem Cells (iPSCs):** Reprogrammed adult cells.
*   **Mesenchymal Stem Cells (MSCs):** Sourced from marrow or adipose tissue.

## Mechanisms of Action
*   Hierarchical regeneration: Stem cells → Progenitor cells → Amplifying cells → Terminally differentiated myocytes.
*   Key functions: Direct differentiation, paracrine signaling, and improved electrical properties.

## Ischemic Heart Disease (IHD) Pathophysiology
*   Atherosclerosis leads to reduced blood flow and cardiomyocyte death.
*   Inflammation triggers homing signals (SDF-1 and VEGF) to attract stem cells.

## Clinical Efficacy
*   Objective: Improve Left Ventricular Ejection Fraction (LVEF) and reduce infarct size.
*   Data indicates functional improvement from baseline (35%) to 6 months post-treatment (48% LVEF in stem cell groups).

## Isolation and Delivery Protocols
*   **Cardiac Biopsy:** Tissue obtained via endomyocardial biopsy for CSC expansion.
*   **Bone Marrow (CD34+):** Mobilized via G-CSF and collected via apheresis.
*   **Intracoronary Infusion:** Uses a balloon catheter for cell delivery relying on chemotaxis.
*   **Intramyocardial Injection:** Electromechanical mapping for direct injection into the transition zone.

## Challenges and Risks
*   **Arrhythmogenesis:** Potential for irregular heartbeats due to poor integration.
*   **Cell Retention:** Risk of cells being washed away (anoikis).
*   **Age-Related Decline:** Lower regenerative capacity in autologous cells from older patients.

## Recent Advances (2026)
*   Enhancing bone marrow cells to reverse fibrosis.
*   Personalized iPSC-derived Cardiac Stem Cells to reduce immune rejection.
*   Integration of gene editing to enhance cell survival.
---
This presentation was created with [Bobr AI](https://bobr.ai) — an AI presentation generator.